Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist
Citations Over TimeTop 10% of 2010 papers
Abstract
GPR40, one of the G protein-coupled receptors predominantly expressed in pancreatic β-cells, mediates enhancement of glucose-stimulated insulin secretion by free fatty acids. A potent and selective GPR40 agonist is theorized to be a safe and effective antidiabetic drug with little or no risk of hypoglycemia. Cyclization of the phenylpropanoic acid moiety of lead compound 1 produced fused phenylalkanoic acids with favorable in vitro agonist activities and pharmacokinetic profiles. Further optimization led to the discovery of dihydrobenzofuran derivative 9a ([(3S)-6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hemi-hydrate, TAK-875) as a potent, selective, and orally bioavailable GPR40 agonist, with a pharmacokinetic profile enabling long-acting drug efficacy. Compound 9a showed potent plasma glucose-lowering action and insulinotropic action during an oral glucose tolerance test in female Wistar fatty rats with impaired glucose tolerance. Compound 9a is currently in clinical trials for the treatment of type 2 diabetes mellitus.
Related Papers
- → Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist(2012)89 cited
- A GEOMETRIC MEAN IN THE FURUTA INEQUALITY(2002)
- → TAK-875 is a Partial Agonist of the Free Fatty Acid Receptor GPR40(2013)
- → The Future of Antidiabetic Drug Development: GPR40-Selective Agonist TAK-875(2010)
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)